On Demand Activities

Evidence Informing Practice: Changing Standards of Care for Use of CDK4 & 6 Inhibitors in the Treatment of Breast Cancer

1.00 hr(s) | CME , MOC , ABIM

Specialty: Breast Cancer

Therapeutic Area(s): Oncology

Release Date: July 17, 2020

Expiration Date: July 16, 2021

Location: Internet Activity Enduring

In this activity, breast cancer experts discuss the latest evidence on the use of CDK4 and 6 inhibitors in the management of patients with HR-positive, HER2-negative breast cancer. An essential overview of mechanisms of action of this therapeutic class, similarities/differences among the agents, and latest approvals/indications is provided, along with a summary and analysis of the current state of the science. Practicalities of clinical integration of the CDK4 and 6 inhibitors are also explored, with a focus on navigating the current treatment landscape and making individualized clinical decisions.

Practical Perspectives on Rapid Change in Endometrial and Cervical Cancer Management: Exploring Innovative Therapy in Gynecologic Malignancies

1.00 hr(s) | CME , MOC , ABIM

Specialty: Gynecologic Cancer

Therapeutic Area(s): Oncology , Gynecology

Release Date: July 17, 2020

Expiration Date: July 16, 2021

Location: Internet Activity Enduring

A panel of gynecologic oncology experts reviews the clinical evidence supporting the use of novel targeted, immunotherapeutic, and antibody-based strategies in gynecologic cancers. Learn the practical aspects of managing patients with advanced endometrial and cervical cancers and gain insight into experts’ in-clinic strategies for selecting the right treatment for the right patient.

How I Think, How I Treat: BTK Inhibitors as a Centerpiece of Care for Hematologic Cancers

1.50 hr(s) | CME , MOC , ABIM

Specialty: BTK

Therapeutic Area(s): Hematology , Oncology

Release Date: July 16, 2020

Expiration Date: July 15, 2021

Location: Internet Activity Enduring

In PeerView’s latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era!

Following the Evidence to Effective Therapy for Myelofibrosis: How Clinicians Can Overcome Challenges in Patient Care in the JAK Inhibitor Era

1.00 hr(s) | CME , MOC , ABIM

Specialty: Myelofibrosis

Therapeutic Area(s): Oncology

Release Date: July 14, 2020

Expiration Date: July 13, 2021

Location: Internet Activity Enduring

The recent approval of newer JAK inhibitors and new evidence on emerging JAK-targeting strategies have raised additional questions over optimized treatment selection in myelofibrosis (MF) and awareness of clinical factors that can influence therapeutic selection. Additionally, newer dynamic risk-assessment models have allowed for more precise characterization of this disease at diagnosis and during the treatment course. In the wake of these advances, understanding how to effectively personalize therapeutic management based on the modern diagnostic and risk-assessment tools while ensuring safe usage of JAK inhibitors is crucial to maximizing beneficial patient outcomes in MF. In a recent live webcast, our panel of experts used the latest real-world evidence to confirm the core therapeutic role for JAK inhibitor–based strategies in MF, highlighting modern diagnostic and risk-assessment strategies that have informed an individualized treatment approach. During a unique practicum session, the panel offered practice strategies using real-world case scenarios, walking through selection of JAK inhibitor–based options across the MF disease continuum to improve patient outcomes.

Patient Stories From the HCC CaseBook: Expert Guidance on Optimizing Outcomes and Care With Newly Available and Emerging Therapies

1.00 hr(s) | CME , MOC , ABIM

Specialty: Hepatocellular Carcinoma

Therapeutic Area(s): Oncology

Release Date: July 14, 2020

Expiration Date: July 13, 2021

Location: Internet Activity Enduring

Liver cancer experts discuss recent developments in the treatment of patients with hepatocellular carcinoma (HCC). Don’t miss this opportunity to learn more about new and emerging treatment strategies and get practical guidance on important clinical treatment decisions, including best practices for therapy sequencing across the disease spectrum and the importance of multidisciplinary care, patient selection, clinical trial enrollment, and adverse event management.

Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer

1.00 hr(s) | CME , MOC , ABIM

Specialty: Lung Cancer

Therapeutic Area(s): Oncology

Release Date: July 14, 2020

Expiration Date: July 13, 2021

Location: Internet Activity Enduring

Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors. This educational on-demand activity based on a recent live webcast features a panel of leading experts who engage in candid conversations about the modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews are framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions.

Transforming Modern Care in AML: Spotlight on Clinical Solutions with Novel Agents for Diverse Patient Populations

1.00 hr(s) | CME , MOC , ABIM

Specialty: Leukemia

Therapeutic Area(s): Hematology , Oncology

Release Date: July 10, 2020

Expiration Date: July 9, 2021

Location: Internet Activity Enduring

In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease.

Chair's Take on Harnessing the Immune System in the Treatment of TNBC and Beyond: Where Are We Now and Where Are We Going Next?

0.50 hr(s) | CME , MOC , ABIM

Specialty: Breast Cancer

Therapeutic Area(s): Oncology

Release Date: July 9, 2020

Expiration Date: July 8, 2021

Location: Internet Activity Enduring

In this activity, Dr. Heather McArthur provides a brief recap of how the emergence of checkpoint inhibitor therapy in TNBC has changed the management of this challenging subtype of breast cancer, and what some of the unanswered questions and controversies are that ongoing research is aiming to answer.

1 2 3 4 12
Copy link
Powered by Social Snap